LENSAR holds commercial launch meeting for ALLY System after FDA clearance

LENSAR, Inc.

LENSAR (LNSR) held commercial launch meeting week of June 27, 2022 for ALLY Adaptive Cataract Treatment System.
Company expects to place 8 to 12 ALLY Systems in a controlled initial launch starting Q3 2022.
ALLY launched with phacoemulsification features disabled; second 510(k) delayed due to predicate device withdrawal.
Supply chain constraints delayed raw material delivery; wider U.S. availability planned for 2023.
LENSAR plans to file CE Mark application in 2022 to commercialize ALLY in the European Union.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.